Caspofungin Acetate in Treating Children With Fever and Neutropenia

You may be eligible if

• DISEASE CHARACTERISTICS:
• Immunocompromised with one or more of the following conditions:
• * Leukemia, lymphoma, or other cancer
• * Underwent bone marrow or peripheral blood stem cell transplantation
• * Aplastic anemia
• Planned chemotherapy likely to incur more than 10 days of neutropenia
• Absolute neutrophil count no greater than 500/mm\^3 AND at least 1 recorded fever over 38.0 ° C within 24 hours of study
• No proven invasive fungal infection at time of study entry
• * Superficial fungal infection (e.g., cutaneous fungal infection, thrush, or candidal vaginitis) treatable with topical antifungals allowed
• PATIENT CHARACTERISTICS:
• Age:
• 2 to 17
• Performance status:
• Not specified
• Life expectancy:
• At least 5 days
• Hematopoietic:
• See Disease Characteristics
• Hemodynamically stable with no hemodynamic compromise
• Hepatic:
• AST or ALT no greater than 3 times upper limit of normal (ULN)
• Alkaline phosphatase no greater than 5 times ULN (unless related to bony metastases or other suspected bony processes)
• INR no greater than 1.6 (4.0 if receiving anticoagulants)
• No acute hepatitis or cirrhosis
• Renal:
• Not specified
• Other:
• Functioning central venous catheter in place
• No other condition or concurrent illness that would preclude study
• No prior allergy, hypersensitivity, or serious reaction to echinocandin antifungals
• HIV negative
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception other than or in addition to oral contraceptives
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• See Disease Characteristics
• Chemotherapy:
• See Disease Characteristics
• Endocrine therapy:
• Not specified
• Radiotherapy:
• Not specified
• Surgery:
• Not specified
• Other:
• No prior enrollment into this study
• No more than 48 hours since prior parenteral systemic antibacterial therapy for fever and neutropenia
• At least 14 days since prior investigational antibiotic or antifungal drugs
• Concurrent topical antifungals (i.e., nystatin and/or azole formulations) for a superficial fungal infection allowed
• No other concurrent investigational drugs, including antibiotics or antifungals
• No concurrent rifampin, cyclosporine, phenytoin, carbamazapine, phenobarbital, or other antifungal treatments (except fluconazole)